Chemotherapy for thymus cancer

Last medical review:

Chemotherapy uses drugs to destroy cancer cells. These drugs target rapidly dividing cells throughout the whole body. This means that chemotherapy kills cancer cells but it can also damage healthy cells.

With most types of chemotherapy, the drugs travel through the blood to reach and destroy cancer cells all over the body, including cells that may have broken away from the primary tumour. This is described as systemic therapy.

Chemotherapy is given for different reasons. You may have chemotherapy to:

  • shrink a tumour before other treatments such as surgery or radiation therapy (called induction chemotherapy)
  • destroy cancer cells left behind after surgery and reduce the risk that the cancer will come back (recur) (called adjuvant chemotherapy)
  • control the growth of cancer cells in the body when the cancer can't be removed with surgery (is inoperable)
  • treat thymus cancer that has come back
  • relieve pain and control other symptoms of advanced thymus cancer (called palliative chemotherapy)

Chemotherapy and radiation therapy may be given during the same time period to treat thymus cancer. This is called chemoradiation. Some chemotherapy drugs can help make radiation work better by making cancer cells more sensitive to radiation. Combining chemotherapy and radiation therapy can be more effective than either treatment on its own.

Chemotherapy and other drugs for thymus cancer

A chemotherapy combination that includes cisplatin is usually used for thymus cancer. It can be given alone or at the same time as radiation therapy.

The most common chemotherapy drug combinations used to treat thymus cancer are:

  • CAP – cisplatin, doxorubicin and cyclophosphamide
  • cisplatin and etoposide
  • CAP with prednisone
  • carboplatin and paclitaxel
  • ADOC – cisplatin, doxorubicin, vincristine and cyclophosphamide
  • VIP – etoposide, ifosfamide and cisplatin
  • gemcitabine, capecitabine and paclitaxel

If thymus cancer doesn’t respond to drugs used in earlier treatments or if it comes back, the following drugs may be used:

  • etoposide
  • fluorouracil (also called 5-fluorouracil or 5-FU)
  • pemetrexed

Chemotherapy for thymus cancer is most often given through a needle into a vein (intravenously or by IV). It’s usually given every 3 weeks. How long chemotherapy treatment is used depends on the type of drug combination. Treatment is usually given for several months.

The following drugs may be given with chemotherapy.

Prednisone is a corticosteroid drug that may be given with the chemotherapy combination. It is given to reduce swelling and lower the body’s immune response (reaction to foreign substances). It is taken as a pill once a day.

Mesna may be given at the same time as ifosfamide or cyclophosphamide. It’s a supportive drug used to protect the bladder from damage and lower the risk of urinary tract problems caused by these chemotherapy drugs. Mesna is given by intravenous (IV).

Octreotide (Sandostatin) is a type of drug called a somatostain analogue. These drugs lower the amount of hormones made and released by cancer cells in the thymus. Octreotide is used to slow and control the growth of advanced or metastatic thymus cancer. It’s given once a month as an injection into the muscle or under the skin. It may be combined with a corticosteroid drug like prednisone.

Side effects

Side effects of chemotherapy will depend mainly on the drug, the dose, how it’s given, and your overall health. Tell your healthcare team if you have side effects that you think are from chemotherapy. The sooner you tell them of any problems, the sooner they can suggest ways to help you deal with them.

Common side effects of chemotherapy drugs for thymus cancer include:

Find out more about chemotherapy

Find out more about chemotherapy and the side effects of chemotherapy. To make the decisions that are right for you, ask your healthcare team questions about chemotherapy.

Details on specific drugs change regularly. Find out more about sources of drug information and where to get details on specific drugs.

Expert review and references

  • Donna Maziak, MD, MSc, FRCPC
  • Falkson CB, Vell ET, Ellis PM, Maziak DE, Ung YC, Yu E. Surgical, radiation and systemic treatments of patients with thymic epithelial tumors: a systematic review. Journal of Thoracic Oncology. 2022: 18(3): 299-312.
  • Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015: Supplement 5:v40-v55.
  • PDQ Adult Treatment Editorial Board. Thymoma and Thymic Carcinoma Treatment (PDQ®) – Health Professional Version. Bethesda, MD: National Cancer Institute; 2024. https://www.cancer.gov/.
  • National Comprehnsive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Thymomas and Thymic Carcinomas Version 2.205. 2025. https://www.nccn.org/home.
  • Cameron RB, Girard N, Lee PP. Neoplasms of the mediastinum. DeVita VT Jr, Lawrence TS, Rosenberg S. eds. DeVita Hellman and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. Philadelphia, PA: Wolters Kluwer; 2023: Kindle version, [chapter 32], https://read.amazon.ca/?asin=B0BG3DPT4Q&language=en-CA.

Your trusted source for accurate cancer information

With support from readers like you, we can continue to provide the highest quality cancer information for over 100 types of cancer.

We’re here to ensure easy access to accurate cancer information for you and the millions of people who visit this website every year. But we can’t do it alone.

Every donation helps fund reliable cancer information, compassionate support services and the most promising research. Please give today because every contribution counts. Thank you.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2026 Canadian Cancer Society